



雅利多證券
ARISTO SECURITIES LIMITED

雅利多證券有限公司
香港灣仔皇后大道東183號合和中心25樓2502室
Room 2502, 25/F., Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong
電話 Tel: +852 3622 1770 傳真 Fax: +852 3622 1488
網站 Website: www.aristo.hk
香港聯合交易所經紀編號 HKEX Broker No.: 2879
證監會中央編號 SFC CE No.: BDH167

17 April 2026

To the Independent Shareholders:

Dear Sir or Madam

**MANDATORY UNCONDITIONAL CASH OFFER BY
ARISTO SECURITIES LIMITED FOR AND ON BEHALF OF
FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED
TO ACQUIRE ALL THE ISSUED SHARES OF
GUANZE MEDICAL INFORMATION INDUSTRY (HOLDING) CO., LTD.
(OTHER THAN THOSE ALREADY
OWNED AND/OR AGREED TO BE ACQUIRED
BY FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED,
ITS ULTIMATE BENEFICIAL OWNERS AND
PARTIES ACTING IN CONCERT WITH ANY OF THEM)**

INTRODUCTION

Reference is made to the Rule 3.7 Announcements published by the Company dated 27 January 2026 and 29 January 2026 and the Joint Announcements jointly published by the Offeror and the Company dated 11 February 2026 and 20 February 2026 in relation to, among other things, the Acquisition and the Offer.

On 28 January 2026, the Offeror (as purchaser) entered into the Sale and Purchase Agreement with the Selling Shareholder (as vendor) for the acquisition of an aggregate of 699,164,575 Sale Shares, representing approximately 73.60% of the total issued share capital of the Company as at the Latest Practicable Date, from the Selling Shareholder at a total Consideration of HK\$174,791,143.75 (equivalent to Consideration of HK\$0.25 per Sale Share). The Consideration was determined after arm's length negotiations between the Selling Shareholder and the Offeror, taking into account, among others, (a) the uncertainties faced by the Group's medical imaging film products business, arising from the market competition and the emergence of alternative products such as digital medical imaging solutions, which have contributed to a significant period-over-period decline in the Group's revenue for the six months ended 30 June 2025; (b) the



thin historical liquidity of the Shares on the Stock Exchange. The average daily trading volume of the Shares for the respective calendar months in the year prior to the entering into of the Sale and Purchase Agreement ranged from approximately 115,000 Shares in July 2025 to approximately 1,726,000 Shares in January 2026, representing approximately 0.012% to 0.182% of the total number of issued Shares as at the Latest Practicable Date; and (c) the then share price performance of the Shares on the Stock Exchange, whereby the increasing trend in the Share price observed only in late January 2026 was not attributable to any discernible fundamental developments of the Group known to the parties to the Sale and Purchase Agreement and may not be sustainable in the long term.

Immediately prior to Completion, none of the Offeror, the ultimate beneficial owners of the Offeror and the parties acting in concert with any of them held any Shares or was interested in any outstanding options, derivatives, warrants or relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) of the Company.

Immediately following Completion and as at the Latest Practicable Date, save for the 699,164,575 Shares, representing approximately 73.60% of the total issued share capital of the Company, held by the Offeror, none of the Offeror, the ultimate beneficial owners of the Offeror and the parties acting in concert with any of them held any Share.

Pursuant to Rule 26.1 of the Takeovers Code, upon Completion, the Offeror is required to make the mandatory unconditional cash offer to acquire all of the Shares in the issued share capital of the Company (other than those already owned and/or agreed to be acquired by the Offeror, the ultimate beneficial owners of the Offeror and the parties acting in concert with any of them). Aristo Securities is, on behalf of the Offeror, making the Offer in compliance with the Takeovers Code on the terms set out in this Composite Document.

This letter forms part of this Composite Document and sets out, among other things, details of the terms of the Offer, the information of the Offeror and the intention of the Offeror in relation to the Group. Further details of the terms and the procedures of acceptance of the Offer are set out in Appendix I to this Composite Document and the accompanying Form of Acceptance.

The Independent Shareholders are strongly advised to consider carefully the information contained in the "Letter from the Board", the "Letter from the Independent Board Committee" and the "Letter from the Independent Financial Adviser", the accompanying Form of Acceptance and the appendices which form part of this Composite Document and to consult their professional advisers if in doubt before reaching a decision as to whether or not to accept the Offer.



THE OFFER

Aristo Securities, for and on behalf of the Offeror and in compliance with the Takeovers Code, is making the Offer on the following basis:

For each Offer ShareHK\$0.25 in cash

The Offer Price of HK\$0.25 per Offer Share under the Offer is equal to the price per Sale Share paid by the Offeror for the 699,164,575 Sale Shares under the Sale and Purchase Agreement.

The Offer is extended to all Shareholders other than the Offeror, the ultimate beneficial owners of the Offeror and parties acting in concert with any of them in accordance with the Takeovers Code. The Offer Shares to be acquired under the Offer shall be fully paid and free from all Encumbrances together with all rights attached thereto, including but not limited to all rights to any dividend or other distribution declared, made or paid on or after the date on which the Offer is made, being the date of despatch of this Composite Document.

The Offer is unconditional in all respects and is not conditional upon acceptances being received in respect of a minimum number of Offer Shares or any other conditions.

The Offeror confirms that the Offer Price is final and will not be increased.

Immediately following Completion and as at the Latest Practicable Date, the Company had 950,000,000 Shares in issue, of which 699,164,575 Shares were held by the Offeror (representing approximately 73.60% of the total issued share capital of the Company).

As at the Latest Practicable Date, there were no other relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) of the Company in issue other than the Shares.

The Board confirms that, as at the Latest Practicable Date, (i) the Company had not declared any dividend or other distribution which remained unpaid; and (ii) it did not have any intention to make, declare or pay any future dividend/make other distributions on or before the close of the Offer.

Further details of the terms of the Offer and the procedures for acceptance of the Offer are set out in Appendix I to this Composite Document and the accompanying Form of Acceptance.



Comparison of value of the Offer Price

The Offer Price of HK\$0.25 per Offer Share represents:

- (i) a discount of approximately 92.7% to the closing price of HK\$3.410 per Share as quoted on the Stock Exchange on the Latest Practicable Date;
- (ii) a discount of approximately 84.0% to the closing price of HK\$1.560 per Share as quoted on the Stock Exchange on the Last Trading Day (i.e. 26 January 2026);
- (iii) a discount of approximately 71.9% to the closing price of HK\$0.890 per Share as quoted on the Stock Exchange on the Last Full Trading Day (i.e. 23 January 2026);
- (iv) a discount of approximately 72.8% to the average closing price of HK\$0.920 per Share, being the average closing price of the Shares as quoted on the Stock Exchange for the five consecutive trading days immediately prior to and including the Last Trading Day;
- (v) a discount of approximately 67.7% to the average closing price of HK\$0.773 per Share, being the average closing price of the Shares as quoted on the Stock Exchange for the 10 consecutive trading days immediately prior to and including the Last Trading Day;
- (vi) a discount of approximately 59.5% to the average closing price of approximately HK\$0.617 per Share, being the average closing price of the Shares as quoted on the Stock Exchange for the 30 consecutive trading days immediately prior to and including the Last Trading Day; and
- (vii) a discount of approximately 8.4% to the audited consolidated net assets per Share of approximately HK\$0.273 as at 31 December 2025, which was calculated based on the audited consolidated net asset value attributable to owners of the Company of approximately RMB231,358,000 (equivalent to approximately HK\$259,745,627) as at 31 December 2025 (the date on which the latest audited financial results of the Group were made up) and 950,000,000 Shares in issue as at the Latest Practicable Date.

Highest and lowest Share prices

During the Relevant Period, the highest closing price of the Shares quoted on the Stock Exchange was HK\$4.450 per Share on 20 February 2026 and the lowest closing price of the Shares quoted on the Stock Exchange was HK\$0.385 per Share on 28 July 2025.



Value of the Offer

As at the Latest Practicable Date, the Company had 950,000,000 Shares in issue. On the basis of the Offer Price being HK\$0.25 per Offer Share, the total issued share capital of the Company would be valued at HK\$237,500,000.

Upon Completion and as at the Latest Practicable Date, save for the 699,164,575 Shares (representing approximately 73.60% of the total issued share capital of the Company as at the Latest Practicable Date) held by the Offeror, and assuming that there is no change in the total issued share capital of the Company up to the close of the Offer, a total of 250,835,425 Shares (representing approximately 26.40% of the total issued share capital of the Company as at the Latest Practicable Date) will be subject to the Offer and the Offer is valued at HK\$62,708,856.25 based on the Offer Price of HK\$0.25 per Offer Share.

Confirmation of financial resources available for the Offer

The maximum payment obligations payable for the Offer shall be payable in cash. The Offeror intends to finance the maximum payment obligations payable for the Offer in full by its own financial resources and no part of such payment obligations will be provided by or borrowed from other parties. The maximum aggregate amount payable by the Offeror for the Offer would be HK\$62,708,856.25 based on the Offer Price of HK\$0.25 per Offer Share assuming full acceptance of the Offer.

Lego Corporate Finance, being the financial adviser to the Offeror in respect of the Offer, is satisfied that sufficient financial resources are and will remain available to the Offeror to satisfy the maximum payment obligations upon full acceptance of the Offer.

Effect of accepting the Offer

Acceptance of the Offer by any Independent Shareholder will be deemed to constitute a warranty by such person that all Offer Shares sold by such person under the Offer are free from all Encumbrances together with all rights attached thereto, including but not limited to all rights to any dividend or other distribution declared, made or paid on or after the date on which the Offer is made, being the date of the despatch of this Composite Document. The Board confirms that, as at the Latest Practicable Date, (i) the Company had not declared any dividend or other distribution which remained unpaid; and (ii) it did not have any intention to make, declare or pay any future dividend/make other distributions on or before the close of the Offer.



The Offer is unconditional in all respects and will not be conditional upon acceptances being received in respect of a minimum number of Offer Shares or any other conditions. Acceptance of the Offer shall be irrevocable and not capable of being withdrawn, except as permitted under the Takeovers Code, details of which are set out in the paragraph headed "6. Right of Withdrawal" in Appendix I to this Composite Document.

Taxation advice

Independent Shareholders are recommended to consult their own professional advisers if they are in any doubt as to the taxation implications of accepting or rejecting the Offer. None of the Offeror, parties acting in concert with it, the Company, Aristo Securities, Lego Corporate Finance, Yue Xiu Capital, the Independent Financial Adviser, and (as the case may be) their respective ultimate beneficial owners, directors, officers, agents, associates, professional advisers or any other person involved in the Offer accepts responsibility for any taxation effects on, or liabilities of, any persons as a result of their acceptance or rejection of the Offer.

Hong Kong Stamp duty

In Hong Kong, seller's ad valorem stamp duty arising in connection with acceptance of the Offer will be payable by the relevant Independent Shareholders at a rate of 0.1% of (i) the market value of the Offer Shares; or (ii) the consideration payable by the Offeror in respect of the relevant acceptance of the Offer, whichever is higher (rounded up to the nearest HK\$1.00), and will be deducted from the cash amount payable by the Offeror to the Independent Shareholders who accept the Offer.

The Offeror will arrange for payment of the seller's ad valorem stamp duty on behalf of the Independent Shareholders accepting the Offer and will pay the buyer's ad valorem stamp duty in connection with the acceptance of the Offer and the transfer of the relevant Offer Shares in accordance with the Stamp Duty Ordinance (Chapter 117 of the Laws of Hong Kong).

Payment

Payment in cash in respect of acceptance of the Offer will be made as soon as possible but, in any event, no later than seven (7) Business Days after the date on which the duly completed acceptance of the Offer is received in accordance with Rule 20.1 of the Takeovers Code. Relevant document(s) evidencing title in respect of such acceptance must be received by or on behalf of the Offeror (or its agent) to render each such acceptance of the Offer complete and valid in accordance with Note 1 to Rule 30.2 of the Takeovers Code.



No fractions of a Hong Kong cent will be payable and the amount of the consideration payable to a Shareholder who accepts the Offer will be rounded up to the nearest Hong Kong cent.

Dealing and interests in the Company's Securities

Save for the Acquisition, none of the Offeror, the ultimate beneficial owners of the Offeror nor the parties acting in concert with any of them had dealt for value in nor owned, controlled or directed any Shares, options, derivatives, warrants or other securities convertible into Shares during the Relevant Period.

Availability of the Offer

The Offeror intends to make the Offer available to all the Independent Shareholders. As the Offer to persons with a registered address in a jurisdiction outside Hong Kong may be affected by the laws of the relevant overseas jurisdictions, Independent Shareholders who are citizens, residents or nationals of a jurisdiction outside Hong Kong should observe any applicable legal or regulatory requirements and, where necessary, seek legal advice. Persons who are residents, citizens or nationals outside Hong Kong should inform themselves about and observe, at their own responsibility, any applicable laws, regulations, requirements and restrictions in their own jurisdictions in connection with the acceptance of the Offer, including the obtaining of any governmental, exchange control or other consents which may be required, or the compliance with the other necessary formalities and the payment of any issue, transfer or other taxes due in respect of such jurisdiction.

As at the Latest Practicable Date, the Company had two Overseas Shareholders with registered addresses situated in the British Virgin Islands. There is no additional requirement for the Offeror to obtain prior approval or consent in the relevant jurisdictions in relation to the extension of the Offer (including despatch of the Composite Document) to such Overseas Shareholders. The Offeror intends to make the Offer available to all the Independent Shareholders, including the Overseas Shareholders.

Any acceptance by the Overseas Shareholders will be deemed to constitute a representation and warranty from such Overseas Shareholders to the Offeror that the local laws and requirements have been complied with and such acceptance shall be valid and binding in accordance with all applicable laws and regulations. Such Overseas Shareholders should consult their respective professional advisers if in doubt.



INFORMATION OF THE GROUP

The Company is a company incorporated in the Cayman Islands on 11 December 2020 as an exempted company with limited liability and its Shares have been listed on the Stock Exchange since 29 December 2022. The Group is a comprehensive medical imaging solutions provider, principally engaged in providing medical imaging film products and medical imaging cloud services in Shandong Province, the PRC. Since the Company's listing and immediately prior to Completion, Meng A Capital Limited had been the controlling shareholder of the Company. Further information on the Group is set out in the paragraph headed "Information on the Group" in the "Letter from the Board" as contained in this Composite Document. Financial Information on the Group is set out in Appendix II to this Composite Document.

INFORMATION OF THE OFFEROR

The Offeror is a company incorporated in Hong Kong with limited liability on 17 September 2015 principally engaged in stock and equity investment. As at the Latest Practicable Date, the Offeror was ultimately beneficially owned as to 94% by Mr. Cheung and as to 6% by Ms. Tao. As at the Latest Practicable Date, the Offeror was directly wholly owned by Funde Holdings (Group) Co., Ltd.* (富德控股(集團)有限公司) (a company established in the PRC) which was in turn held as to approximately 49.1%, 44.9%, 3.6% and 2.4% by Shenzhen City Junde Investment Co., Ltd.* (深圳市峻德投資有限公司) (a company established in the PRC) (which was wholly owned by Mr. Cheung), Mr. Cheung, Shenzhen City Fuyuanxiang Investments Co., Ltd.* (深圳市富源祥投資有限公司) (a company established in the PRC) (which was wholly owned by Ms. Tao) and Ms. Tao, respectively. The sole director of the Offeror is Mr. Zhang.

Mr. Cheung, aged 62, is the ultimate controlling shareholder of the Offeror. Mr. Cheung possesses over 20 years of business operations and management experience in the insurance and financial services industries. He is currently the director and chairman of the board of Funde Holdings (Group) Co., Ltd.* (富德控股(集團)有限公司) ("**Funde Holdings**") (in which Mr. Cheung ultimately beneficially owns 94% equity interest and Ms. Tao ultimately beneficially owns 6% equity interest) and the chairman of the board of Funde Insurance Holdings Co., Ltd.* (富德保險控股股份有限公司) ("**Funde Insurance**") (in which Funde Holdings indirectly holds approximately 20.0% equity interest). From March 2002 to July 2014, he served at Funde Sino Life Insurance Company Ltd.* (富德生命人壽保險股份有限公司) ("**Funde Sino**") (in which Funde Holdings indirectly holds approximately 22.1% equity interest), with his last position being the chairman of the board.



Mr. Cheung, leveraging his extensive expertise in business operations and management, aims to explore new industry sectors through strategic investments and acquisitions. Also, Mr. Cheung considers that the Acquisition presents a compelling investment opportunity based on his optimistic assessment of the future outlook of the industry the Group operates in.

Notwithstanding that background and experience of the ultimate beneficial owners or sole director of the Offeror may not directly correlate with the Group's principal business, Mr. Cheung possesses extensive experience in business operations and management in various industries (such as insurance, financial services and healthcare through his work experience at Funde Holdings, Funde Insurance and Funde Sino) and strategic leadership capabilities. By partnering with Mr. Cheung, the Company will have the opportunity to benefit from his profound experience in business operations and management to further enhance its competitive position in the rapidly evolving industry landscape in which the Group operates (i.e. the provision of medical imaging film products and medical imaging cloud services in the PRC) for long-term growth. In particular, it is crucial for the Group to ensure that its products and services remain robust and up-to-date in response to evolving customer preference and market trends. As set out in the Company's interim report for the six months ended 30 June 2025, the Group's strategic plans include expansion of customer base, enhancement in delivery of medical imaging cloud services through strategic acquisition, horizontal expansion of its value chain and increase in market awareness. Mr. Cheung's extensive managerial experience will assist the Company in formulating business strategies (including pursuing investment, acquisition and strategic opportunities) and establishing and maintaining business relationships with existing and potential customers in order to increase the Group's market presence and explore new business opportunities for its long-term sustainable development.

The Offeror and its ultimate beneficial owners were Independent Third Parties prior to Completion.

Immediately before Completion, none of the Offeror, its ultimate beneficial owners, its director and the parties acting in concert with any of them held any Shares. Immediately after Completion and as at the Latest Practicable Date, none of the Offeror, the ultimate beneficial owners and director of the Offeror (i.e. Mr. Zhang) and the parties acting in concert with any of them held any Shares or other relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) of the Company, save for the 699,164,575 Sale Shares acquired by the Offeror through the Acquisition.



THE OFFEROR'S INTENTION ON THE GROUP

Following the close of the Offer, it is the intention of the Offeror that the Group will continue with its existing principal business for long-term purposes. The Offeror does not intend to introduce any major changes to the existing operations and business of the Group after close of the Offer and will neither redeploy nor dispose of any of the assets (including fixed assets) of the Group other than in the ordinary course of business. As at the Latest Practicable Date, (i) the Offeror did not have any intention, understanding, negotiation, arrangement, and agreements (formal or informal, express or implied) to downsize or dispose of any existing business or assets of the Group; and (ii) no investment or business opportunity had been identified nor had the Offeror entered into any agreement, arrangement, understanding or negotiation in relation to (a) the injection of any assets or business into the Group; or (b) the disposal of any assets or business of the Group.

Nevertheless, following the close of the Offer, the Offeror will conduct a detailed review on the existing principal operations and business, and the financial position of the Group for the purpose of formulating business plans and strategies for the Group's long-term business development and will explore other business opportunities for the Group. Subject to the results of the review, and should suitable investment or business opportunities arise, the Offeror may consider whether any assets and/or business acquisitions or disposals by the Group will be appropriate in order to enhance its growth. Any acquisition or disposal of the assets or business of the Group, if any, will be conducted in compliance with the Listing Rules.

As at the Latest Practicable Date, the Board comprised two executive Directors, one non-executive Director and three independent non-executive Directors. The Offeror intends to continue the employment of the existing management and employees of the Group. As at the Latest Practicable Date, the Offeror had no intention to (i) nominate new Directors to the Board or otherwise change the composition of the Board; (ii) make material changes to the employment of the management and employees of the Group; and (iii) dispose of or redeploy the assets of the Group other than those in its ordinary and usual course of business. However, the Offeror reserves the right to make any changes that it deems necessary or appropriate to the composition of the Board, the Group's businesses and operations to optimise the value of the Group. Any changes to the members of the Board will be made in compliance with the Takeovers Codes and/or the Listing Rules and further announcement(s) will be made as and when appropriate.



PUBLIC FLOAT AND MAINTENANCE OF THE LISTING STATUS OF THE COMPANY

Pursuant to the Listing Rules, the Stock Exchange has stated that

- (a) if, at the close of the Offer, the Stock Exchange believes that:
 - (i) a false market exists or may exist in the trading of the Shares; or
 - (ii) an orderly market does not exist or may not exist;

it will consider exercising its discretion to suspend dealings in the Shares; and

- (b) if, at the close of the offer, the Company has a Significant Public Float Shortfall (as defined in Rule 13.32F of the Listing Rules), then:
 - (i) the Stock Exchange will add a designated marker to the stock name of the Shares; and
 - (ii) the Stock Exchange will cancel the listing of the Shares if the Company fails to re-comply with Rule 13.32B of the Listing Rules for a continuous period of 18 months from the commencement of the Significant Public Float Shortfall.

Therefore, it should be noted that upon close of the Offer, there may be insufficient public float of the Shares. The Company will make an application to the Stock Exchange for a temporary waiver from strict compliance with Rule 8.08(1)(a) of the Listing Rules in case less than 25% of the issued share capital of the Company will be held by the public upon the close of the Offer in accordance with Rule 13.33 of the Listing Rules. Appropriate steps will be taken to ensure public float will be restored as soon as possible after the close of the Offer. The steps that the Offeror may take include but not limited to placing down or selling sufficient number of accepted Shares it acquired from the Offer to selected Independent Third Parties or in the market. No arrangements had been confirmed or put in place as at the Latest Practicable Date.

Further announcement(s) will be made in accordance with the requirements of the Listing Rules and the Takeovers Code as and when appropriate. Further announcement(s) regarding the restoration of public float will be made by the Company as and when appropriate.



The Offeror intends the Company to remain listed on the Stock Exchange following the close of the Offer. Each of the sole director of the Offeror and the Directors has jointly and severally undertaken to the Stock Exchange that if, at the close of the Offer, the Company fails to comply with the requirement of Rule 13.32B of the Listing Rules, they will take appropriate steps to ensure the Company's compliance with Rule 13.32B of the Listing Rules at the earliest possible moment.

ACCEPTANCE AND SETTLEMENT

Your attention is drawn to the further details regarding further terms and conditions of the Offer, the procedures for acceptance and settlement and the acceptance period as set out in Appendix I to this Composite Document and the accompanying Form of Acceptance.

COMPULSORY ACQUISITION

The Offeror does not intend to avail itself of any powers of compulsory acquisition of any Shares outstanding after the close of the Offer.

GENERAL

This Composite Document has been prepared for the purposes of complying with the laws of Hong Kong, the Takeovers Code and the Listing Rules and the information disclosed may not be the same as which would have been disclosed if this Composite Document had been prepared in accordance with the laws of jurisdictions outside Hong Kong.

To ensure equality of treatment of all Independent Shareholders, those Independent Shareholders who hold Shares as nominee on behalf of more than one beneficial owner should, as far as practicable, treat the holding of such beneficial owner separately. It is essential for the beneficial owners of the Shares whose investments are registered in the names of nominees to provide instructions to their nominees of their intentions with regard to the Offer.

Attention of the Overseas Shareholders is drawn to the paragraph headed "7. Overseas Shareholders" in Appendix I to this Composite Document. All communications, notices, Form of Acceptance, share certificate(s), transfer receipt(s), other document(s) of title (and/or any satisfactory indemnity or indemnities required in respect thereof) and remittances to settle the consideration payable under the Offer to be delivered by or sent to or from the Independent Shareholders will be delivered by or sent to or from them, or their designated agents, by ordinary post at their own risk. None of the Offeror, its ultimate beneficial owners and the parties acting in concert with any of them, the Company, Aristo Securities, Lego Corporate Finance, Yue Xiu Capital, the Independent Financial Adviser, the Registrar or (as the case may be) their respective



ultimate beneficial owners, directors, officers, agents and associates nor any other person involved in the Offer will be responsible for any loss or delay in postage or any other liabilities that may arise as a result thereof or in connection therewith. Further details have been set out in Appendix I to this Composite Document and in the accompanying Form of Acceptance.

ADDITIONAL INFORMATION

Your attention is drawn to the additional information set out in the appendices to this Composite Document and the accompanying Form of Acceptance, which form part of this Composite Document. You are reminded to carefully read the “Letter from the Board”, the “Letter from the Independent Board Committee”, the “Letter from the Independent Financial Adviser” and other information about the Group, which are set out in this Composite Document and the accompanying Form of Acceptance before deciding whether or not to accept the Offer.

In considering what action to take in connection with the Offer, you should consider your own tax or financial position and if you are in any doubt, you should consult your professional advisers.



雅利多證券
ARISTO SECURITIES LIMITED

雅利多證券有限公司
香港灣仔皇后大道東183號合和中心25樓2502室
Room 2502, 25/F., Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong
電話 Tel: +852 3622 1770 傳真 Fax: +852 3622 1488
網站 Website: www.aristo.hk
香港聯合交易所經紀編號 HKEX Broker No.: 2879
證監會中央編號 SFC CE No.: BDH167

**Yours faithfully,
For and on behalf of
Aristo Securities Limited**

For and on behalf of
ARISTO SECURITIES LIMITED
雅利多證券有限公司

.....
Authorized Signature(s)

**Name: Wan Wai Ching Lilian
Position: Director**